terça-feira, abril 05, 2005

FDA aprova novo medicamento contra hepatite B

The US Food and Drug Administration (FDA) announced yesterday that on March 29th it approved entecavir, marketed by Bristol-Myers Squibb (BMS) as Baraclude, for the treatment of chronic hepatitis B virus for individuals monoinfected with hepatitis B and individuals coinfected with both HIV and hepatitis B who have previously received 3TC (lamivudine, Epivir/Zeffix).

Comments: Enviar um comentário

<< Home

This page is powered by Blogger. Isn't yours?

Enter your email address below to subscribe to Blog do GAT!

powered by Bloglet